Trial · NCT03123783
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Experiencing Dose-limiting Toxicities (DLTs) | Phase 1b Escalation | 0 | Participants | ||
| Maximum Tolerated Dose (MTD) of APX005M + Nivolumab (Phase 1b) | Phase 1b Escalation | NA | mg/kg | ||
| Phase 2 Evaluate the Objective Response Rate (ORR) by RECIST 1.1 and iRECIST in Each Cohort / Group | Cohort 1 (Arm)/inNSCLC (Phase 2) | 16.67 | 90% Confidence Interval 8.57 to 28.07 | Percentage of participants | |
| Phase 2 Evaluate the Objective Response Rate (ORR) by RECIST 1.1 and iRECIST in Each Cohort / Group | Cohort 2(Arm)/PD1-MM (Phase 2) | 15.15 | 90% Confidence Interval 6.17 to 29.25 | Percentage of participants | |
| Phase 2 Evaluate the Objective Response Rate (ORR) by RECIST 1.1 and iRECIST in Each Cohort / Group | Cohort 3A(Arm)/PD1-NSCLC (Phase 2) | 0.00 | 90% Confidence Interval 0.00 to 22.09 | Percentage of participants | |
| Phase 2 Evaluate the Objective Response Rate (ORR) by RECIST 1.1 and iRECIST in Each Cohort / Group | Cohort 3B(Arm)/PD1-NSCLC (Phase 2) | 0.00 | 90% Confidence Interval 0.00 to 11.29 | Percentage of participants | |
| Safety of the APX005M and Nivolumab Combination (Phase 2) | Cohort 1 (Arm)/inNSCLC (Phase 2) | 52 | Participants | ||
| Safety of the APX005M and Nivolumab Combination (Phase 2) | Cohort 2(Arm)/PD1-MM (Phase 2) | 36 | Participants | ||
| Safety of the APX005M and Nivolumab Combination (Phase 2) | Cohort 3A(Arm)/PD1-NSCLC (Phase 2) | 14 | Participants | ||
| Safety of the APX005M and Nivolumab Combination (Phase 2) | Cohort 3B(Arm)/PD1-NSCLC (Phase 2) | 28 | Participants | ||
| Duration of Response (DOR) as Per RECIST 1.1(Phase 2) | Cohort 1(Arm)/inNSCLC (Phase 2) | NA | Full Range 3.9 to 21.4 | Months | |
| Duration of Response (DOR) as Per RECIST 1.1(Phase 2) | Cohort 2(Arm)/PD1-MM (Phase 2) | NA | Full Range 4.2 to 24.7 | Months | |
| Median Progression-free Survival (PFS) (Phase 2) | Cohort 1(Arm)/inNSCLC (Phase 2) | 4.11 | 90% Confidence Interval 3.45 to 5.52 | Months | |
| Median Progression-free Survival (PFS) (Phase 2) | Cohort 2(Arm)/PD1-MM (Phase 2) | 1.97 | 90% Confidence Interval 1.87 to 3.61 | Months | |
| Median Progression-free Survival (PFS) (Phase 2) | Cohort 3A(Arm)/PD1-NSCLC (Phase 2) | 3.43 | 90% Confidence Interval 2.00 to 3.88 | Months | |
| Median Progression-free Survival (PFS) (Phase 2) | Cohort 3B(Arm)/PD1-NSCLC (Phase 2) | 3.65 | 90% Confidence Interval 1.84 to 3.81 | Months | |
| 6-month PFS Rate (Phase 2) | Cohort 1(Arm)/inNSCLC (Phase 2) | 33.10 | 90% Confidence Interval 20.10 to 46.68 | Percentage of participants | |
| 6-month PFS Rate (Phase 2) | Cohort 2(Arm)/PD1-MM (Phase 2) | 21.21 | 90% Confidence Interval 9.35 to 36.25 | Percentage of participants | |
| 6-month PFS Rate (Phase 2) | Cohort 3A(Arm)/PD1-NSCLC (Phase 2) | 25.00 | 90% Confidence Interval 6.01 to 50.48 | Percentage of participants | |
| 6-month PFS Rate (Phase 2) | Cohort 3B(Arm)/PD1-NSCLC (Phase 2) | 12.92 | 90% Confidence Interval 3.27 to 29.41 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03123783/results